Net profit of Ozon Pharmaceuticals under IFRS for 2025 increased by 34% to RUB 6.17 billion from RUB 4.6 billion a year earlier. Such data is provided by the company.
Revenue increased by 24% to 31.59 billion rubles from 25.56 billion rubles, gross profit – by 29% to 15.07 billion rubles from 11.7 billion rubles, adjusted EBITDA – by 28% to 12.18 billion rubles from 9.48 billion rubles.
The volume of capital investments decreased by 7% to RUB 4 billion. Investments include registration of chemical pharmaceuticals and biologics (2 billion rubles), construction and purchase of equipment for Ozon Medica (1.1 billion rubles) and Mabscale (262 million rubles), as well as purchase of equipment and maintenance at other plants of the group (593 million rubles). Reduction of capital expenditures is associated with the planned a decrease in the amount of investments in the purchase of equipment at Mabscale and Ozon Medica enterprises compared to 2024, as well as the strengthening of the ruble exchange rate.
In 2025, Ozon Pharmaceuticals implemented an SPO deal and a subsequent additional share issue, under which the company raised about 2.9 billion rubles. The funds raised are aimed at implementing a growth strategy, including developing a portfolio of high-tech drugs and launching new production facilities.
In the reporting period, the Board of Directors approved the sale of the company's quasi-treasury shares. The management plans to gradually sell the shares to the market by the end of 2026.
On February 27, 2026, on the recommendation of the index committee, the Moscow Stock Exchange approved a new free-float ratio of the company's shares at 20% in connection with the clarification of the share capital structure based on information from the company.
Ozon Pharmaceuticals Group is a Russian pharmaceutical company. The company's products are represented in all pharmaceutical niches. Ozon Pharmaceuticals has 16 operating production sites certified according to GMP standards. All production facilities are located in the Samara region (Tolyatti and Zhigulevsk), research laboratories are also located in the Skolkovo biopharmaceutical cluster and in the city of Khimki.
The company was founded in 2001. Shares of PJSC Ozon Pharmaceuticals (OZPH) have been traded on the Moscow Stock Exchange since 2024, are part of the innovation and investment market sector (RII of the Moscow Stock Exchange) and a set of stock indices of the Moscow Stock Exchange.
The net profit of PJSC Ozon Pharmaceuticals for the first 9 months of 2025 increased by 50% to 3.445 billion rubles from 2.3 billion rubles a year earlier. Revenue increased by 28% to 21.433 billion rubles from 16.763 billion rubles, gross profit — by 33% to 9.696 billion rubles from 7.278 billion rubles, adjusted EBITDA — by 34% to 7.739 billion rubles from 5.791 billion rubles, capital expenditures — by 23% to 2.99 billion rubles from 2.426 billion rubles.
